Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 14, 2013; 19(22): 3473-3480
Published online Jun 14, 2013. doi: 10.3748/wjg.v19.i22.3473
Published online Jun 14, 2013. doi: 10.3748/wjg.v19.i22.3473
Figure 1 Correlation of overall survival with type of treatment.
All 45 patients with metastatic hepatocellular carcinoma died before June, 2012. There were 21 patients in the cryo-immunotherapy group, 12 in the cryotherapy group, five in the immunotherapy group and seven in the untreated group. The overall follow-up period was 8 years. A: Overall survival (OS) of patients who underwent comprehensive cryosurgery with or without transarterial chemoembolization (TACE). Thirty-three patients were enrolled; based on the long diameter of their hepatic tumors (≥ 5 cm), 25 underwent TACE before hepatic cryoablation. Kaplan-Meier test with long-rank analysis; B: OS in the cryo-immunotherapy, cryotherapy and/or immunotherapy groups vs that in the untreated group using the Dunnett test. Horizontal lines represent the average and standard deviation. aP < 0.05, bP < 0.01 vs untreated group.
Figure 2 Overall survival of patients who underwent comprehensive cryosurgery with or without immunotherapy.
The Kaplan-Meier test with log-rank analysis was used to compare the overall survival of 21 patients in the cryo-immunotherapy group with that of 12 patients in the cryotherapy group.
Figure 3 Correlation of overall survival with number of cryo- and/or immunotherapy procedures, using the Kaplan-Meier test with long-rank analysis.
A: Comparison of overall survival (OS) between 10 patients who underwent repeated treatments and 11 patients who underwent a single treatment in the cryo-immunotherapy group; B: Comparison of OS between six patients who underwent repeated cryoablation and six who underwent a single cryoablation in the cryotherapy group.
- Citation: Niu LZ, Li JL, Zeng JY, Mu F, Liao MT, Yao F, Li L, Liu CY, Chen JB, Zuo JS, Xu KC. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer. World J Gastroenterol 2013; 19(22): 3473-3480
- URL: https://www.wjgnet.com/1007-9327/full/v19/i22/3473.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i22.3473